ARCHIVES

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

This article is from The Cancer Letter archive.

Vol. 34 No. 10 | October 28, 2011

Download PDF Visit The Full Archive

Related Articles

NTP Board Approves Four New Concepts

October 8, 1982

NIH Eyes FCRC For Intramural Space As Contract Recompetition Planning Nears

May 23, 1980

In Brief: Marasco New ACR President, Barbara Chick VP; Wolmark Named Surgeon In Chief Of Montefiore

October 10, 1986

Bloch Dissatisfied With PDQ, Offers $1 Million To fund “Tailored” Treatment Data To Physicians

November 13, 1987

President Signs Supplemental Funding For NIH And FDA.

July 11, 2008

Clinical Trials System “Slowly Unraveling,”

March 7, 2008